Details of the Drug

General Information of Drug (ID: DM7NKEV)

Drug Name
Thioguanine
Synonyms
6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)
Indication
Disease Entry ICD 11 Status REF
Acute lymphocytic leukaemia 2B33.3 Approved [1]
Acute myelogenous leukaemia 2A41 Approved [2]
Acute myeloid leukaemia 2A60 Approved [3]
Middle East Respiratory Syndrome (MERS) 1D64 Preclinical [4]
Severe acute respiratory syndrome (SARS) 1D65 Preclinical [4]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 167.19
Logarithm of the Partition Coefficient (xlogp) -0.1
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [5]
Clearance
The drug present in the plasma can be removed from the body at the rate of 15.4 mL/min/kg [6]
Elimination
0.5% of drug is excreted from urine in the unchanged form [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 24.35 hours [6]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 2.89 L/kg [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.2 mg/mL [5]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Bone marrow toxicity Not Available TPMT OTFOX70W [7]
Chemical Identifiers
Formula
C5H5N5S
IUPAC Name
2-amino-3,7-dihydropurine-6-thione
Canonical SMILES
C1=NC2=C(N1)C(=S)N=C(N2)N
InChI
InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)
InChIKey
WYWHKKSPHMUBEB-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2723601
ChEBI ID
CHEBI:9555
CAS Number
154-42-7
DrugBank ID
DB00352
TTD ID
D02ZXM
VARIDT ID
DR00510
INTEDE ID
DR1597
ACDINA ID
D00671
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Inosine-5'-monophosphate dehydrogenase (IMPDH) TTCAQMW NOUNIPROTAC Intercalator [8]
MERS-CoV papain-like proteinase (PL-PRO) TTYJOLE R1AB_CVEMC (854-2740) Inhibitor [4]
SARS-CoV papain-like proteinase (PL-PRO) TTRGHB2 R1AB_CVHSA (819-2740) Inhibitor [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Concentrative Na(+)-nucleoside cotransporter 3 (SLC28A3) DT4YL5R S28A3_HUMAN Substrate [9]
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [10]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Hypoxanthine phosphoribosyltransferase (HPRT1) DEVXTP5 HPRT_HUMAN Substrate [12]
Thiopurine methyltransferase (TPMT) DEFQ8VO TPMT_HUMAN Substrate [13]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
ATP-binding cassette sub-family C member 5 (ABCC5) OT34G4US MRP5_HUMAN Drug Response [14]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Drug Response [15]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Drug Response [16]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Gene/Protein Processing [16]
DNA mismatch repair protein Msh2 (MSH2) OT10H1AB MSH2_HUMAN Drug Response [17]
Dystrophin (DMD) OTD21T5J DMD_HUMAN Gene/Protein Processing [18]
Hypoxanthine-guanine phosphoribosyltransferase (HPRT1) OTOEEEXG HPRT_HUMAN Drug Response [19]
Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) OTPG0K7E IMDH2_HUMAN Gene/Protein Processing [20]
Occludin (OCLN) OTSUTVWL OCLN_HUMAN Gene/Protein Processing [21]
Thiopurine S-methyltransferase (TPMT) OTFOX70W TPMT_HUMAN Drug Response [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Thioguanine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Tagraxofusp DM9HQ5U Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Tagraxofusp. Acute myeloid leukaemia [2A60] [22]
Gilteritinib DMTI0ZO Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Gilteritinib. Acute myeloid leukaemia [2A60] [22]
Coadministration of a Drug Treating the Disease Different from Thioguanine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [23]
Tretinoin DM49DUI Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Tretinoin. Acne vulgaris [ED80] [22]
Isotretinoin DM4QTBN Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Isotretinoin. Acne vulgaris [ED80] [22]
Nicotinamide DMUPE07 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Nicotinamide. Acquired cutaneous blood vessel malformation [EF20] [22]
Pioglitazone DMKJ485 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Pioglitazone. Acute diabete complication [5A2Y] [22]
Chlorzoxazone DMCYVDT Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Chlorzoxazone. Acute pain [MG31] [22]
Oxandrolone DMU9MYJ Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Oxandrolone. Alcoholic liver disease [DB94] [22]
Tacrine DM51FY6 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Tacrine. Alzheimer disease [8A20] [22]
Inotersen DMJ93CT Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Inotersen. Amyloidosis [5D00] [22]
Dronedarone DMA8FS5 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Dronedarone. Angina pectoris [BA40] [22]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [24]
Oxymetholone DMFXUT8 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Oxymetholone. Aplastic anaemia [3A70] [22]
Voriconazole DMAOL2S Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Voriconazole. Aspergillosis [1F20] [22]
Posaconazole DMUL5EW Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Posaconazole. Aspergillosis [1F20] [22]
Zafirlukast DMHNQOG Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Zafirlukast. Asthma [CA23] [22]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Thioguanine and Roflumilast. Asthma [CA23] [25]
Zileuton DMVRIC2 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Zileuton. Asthma [CA23] [22]
Ofloxacin DM0VQN3 Minor Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [26]
Clavulanate DM2FGRT Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Clavulanate. Bacterial infection [1A00-1C4Z] [22]
Ciprofloxacin XR DM2NLS9 Minor Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [26]
Clarithromycin DM4M1SG Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Clarithromycin. Bacterial infection [1A00-1C4Z] [22]
Trovafloxacin DM6AN32 Minor Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Trovafloxacin. Bacterial infection [1A00-1C4Z] [26]
Sulfamethoxazole DMB08GE Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [22]
Sparfloxacin DMB4HCT Minor Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [26]
Gemifloxacin DMHT34O Minor Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [26]
Norfloxacin DMIZ6W2 Minor Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [26]
ABT-492 DMJFD2I Minor Decreased absorption of Thioguanine due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [26]
Levofloxacin DMS60RB Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Levofloxacin. Bacterial infection [1A00-1C4Z] [22]
Troleandomycin DMUZNIG Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Troleandomycin. Bacterial infection [1A00-1C4Z] [22]
Minocycline DMVN5OH Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Minocycline. Bacterial infection [1A00-1C4Z] [22]
Lomefloxacin DMVRH9C Minor Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [26]
Telithromycin DMZ4P3A Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Telithromycin. Bacterial infection [1A00-1C4Z] [22]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Thioguanine and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [27]
Lomustine DMMWSUL Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Lomustine. Brain cancer [2A00] [22]
Lapatinib DM3BH1Y Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Lapatinib. Breast cancer [2C60-2C6Y] [22]
LY2835219 DM93VBZ Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and LY2835219. Breast cancer [2C60-2C6Y] [22]
Pralatrexate DMAO80I Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Pralatrexate. Breast cancer [2C60-2C6Y] [22]
Tucatinib DMBESUA Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Tucatinib. Breast cancer [2C60-2C6Y] [22]
Tamoxifen DMLB0EZ Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Tamoxifen. Breast cancer [2C60-2C6Y] [22]
Bosutinib DMTI8YE Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Bosutinib. Breast cancer [2C60-2C6Y] [22]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [22]
Fluoxymesterone DMUHCF1 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Fluoxymesterone. Breast cancer [2C60-2C6Y] [22]
Grepafloxacin DMGLX0T Minor Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Grepafloxacin. Bronchitis [CA20] [26]
Atorvastatin DMF28YC Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Atorvastatin. Cardiovascular disease [BA00-BE2Z] [22]
Fenofibric acid DMGO2MC Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Fenofibric acid. Cardiovascular disease [BA00-BE2Z] [22]
Macitentan DMP79A1 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Macitentan. Cardiovascular disease [BA00-BE2Z] [22]
Chenodiol DMQ8JIK Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Chenodiol. Cholelithiasis [DC11] [22]
Phenylbutazone DMAYL0T Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Phenylbutazone. Chronic pain [MG30] [22]
Ketoprofen DMRKXPT Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Ketoprofen. Chronic pain [MG30] [22]
Regorafenib DMHSY1I Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Regorafenib. Colorectal cancer [2B91] [22]
Oxaliplatin DMQNWRD Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Oxaliplatin. Colorectal cancer [2B91] [22]
Intedanib DMSTA36 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Intedanib. Colorectal cancer [2B91] [22]
Pasireotide DMHM7JS Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Pasireotide. Cushing syndrome [5A70] [22]
Ivacaftor DMZC1HS Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Ivacaftor. Cystic fibrosis [CA25] [22]
Ethanol DMDRQZU Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Ethanol. Cystitis [GC00] [22]
Nefazodone DM4ZS8M Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Nefazodone. Depression [6A70-6A7Z] [22]
Duloxetine DM9BI7M Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Duloxetine. Depression [6A70-6A7Z] [22]
Milnacipran DMBFE74 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Milnacipran. Depression [6A70-6A7Z] [22]
Polatuzumab vedotin DMF6Y0L Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [22]
PMID28454500-Compound-96 DM2A75P Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and PMID28454500-Compound-96. Discovery agent [N.A.] [22]
Felbamate DM1V5ZS Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Felbamate. Epilepsy/seizure [8A61-8A6Z] [22]
Mephenytoin DM5UGDK Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Mephenytoin. Epilepsy/seizure [8A61-8A6Z] [22]
Fosphenytoin DMOX3LB Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [22]
Ethotoin DMXWOCP Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Ethotoin. Epilepsy/seizure [8A61-8A6Z] [22]
Carbamazepine DMZOLBI Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Carbamazepine. Epilepsy/seizure [8A61-8A6Z] [22]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Cannabidiol. Epileptic encephalopathy [8A62] [25]
Mefenamic acid DMK7HFI Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Mefenamic acid. Female pelvic pain [GA34] [22]
Dantrolene DM1D8XY Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Dantrolene. Fever [MG26] [22]
Itraconazole DMCR1MV Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Itraconazole. Fungal infection [1F29-1F2F] [22]
Caspofungin DMGQIPT Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Caspofungin. Fungal infection [1F29-1F2F] [22]
Terbinafine DMI6HUW Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Terbinafine. Fungal infection [1F29-1F2F] [22]
Ketoconazole DMPZI3Q Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Ketoconazole. Fungal infection [1F29-1F2F] [22]
Atovaquone DMY4UMW Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Atovaquone. Fungal infection [1F29-1F2F] [22]
Sunitinib DMCBJSR Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [22]
Lamivudine DMI347A Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Lamivudine. Hepatitis virus infection [1E50-1E51] [22]
177Lu-DOTATATE DMT8GVU Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [22]
Isoniazid DM5JVS3 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Isoniazid. HIV-infected patients with tuberculosis [1B10-1B14] [22]
Rifampin DMA8J1G Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Rifampin. HIV-infected patients with tuberculosis [1B10-1B14] [22]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Brentuximab vedotin. Hodgkin lymphoma [2B30] [22]
Zidovudine DM4KI7O Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Zidovudine. Human immunodeficiency virus disease [1C60-1C62] [22]
Tipranavir DM8HJX6 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [22]
Emtricitabine DMBMUWZ Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Emtricitabine. Human immunodeficiency virus disease [1C60-1C62] [22]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [22]
Zalcitabine DMH7MUV Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [22]
Rilpivirine DMJ0QOW Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [22]
Abacavir DMMN36E Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Abacavir. Human immunodeficiency virus disease [1C60-1C62] [22]
Darunavir DMN3GCH Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Darunavir. Human immunodeficiency virus disease [1C60-1C62] [22]
Maraviroc DMTL94F Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [22]
Ritonavir DMU764S Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Ritonavir. Human immunodeficiency virus disease [1C60-1C62] [22]
Simvastatin DM30SGU Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Simvastatin. Hyper-lipoproteinaemia [5C80] [22]
Fluvastatin DM4MDJY Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Fluvastatin. Hyper-lipoproteinaemia [5C80] [22]
Fenofibrate DMFKXDY Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Fenofibrate. Hyper-lipoproteinaemia [5C80] [22]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Thioguanine and Mipomersen. Hyper-lipoproteinaemia [5C80] [28]
Rosuvastatin DMMIQ7G Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Rosuvastatin. Hyper-lipoproteinaemia [5C80] [22]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Thioguanine and Teriflunomide. Hyper-lipoproteinaemia [5C80] [29]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Thioguanine and BMS-201038. Hyper-lipoproteinaemia [5C80] [30]
Cerivastatin DMXCM7H Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Cerivastatin. Hyper-lipoproteinaemia [5C80] [22]
Moexipril DM26E4B Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Moexipril. Hypertension [BA00-BA04] [22]
Trandolapril DM4L6EU Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Trandolapril. Hypertension [BA00-BA04] [22]
Methyldopa DM5I621 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Methyldopa. Hypertension [BA00-BA04] [22]
Fosinopril DM9NJ52 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Fosinopril. Hypertension [BA00-BA04] [22]
Benazepril DMH1M9B Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Benazepril. Hypertension [BA00-BA04] [22]
Labetalol DMK8U72 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Labetalol. Hypertension [BA00-BA04] [22]
Enalapril DMNFUZR Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Enalapril. Hypertension [BA00-BA04] [22]
Perindopril DMOPZDT Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Perindopril. Hypertension [BA00-BA04] [22]
Quinapril DMR8H31 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Quinapril. Hypertension [BA00-BA04] [22]
Lisinopril DMUOK4C Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Lisinopril. Hypertension [BA00-BA04] [22]
Tolvaptan DMIWFRL Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [22]
Pirfenidone DM6VZFQ Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Pirfenidone. Idiopathic interstitial pneumonitis [CB03] [22]
Vitamin B3 DMQVRZH Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Vitamin B3. Inborn lipid metabolism error [5C52] [22]
Givosiran DM5PFIJ Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [22]
Febuxostat DMDEXQ0 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Febuxostat. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [22]
Balsalazide DM7I1T9 Moderate Decreased metabolism of Thioguanine caused by Balsalazide mediated inhibition of non-CYP450 enzyme. Indeterminate colitis [DD72] [31]
Meclofenamic acid DM05FXR Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [22]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Methotrexate. Leukaemia [2A60-2B33] [25]
Testosterone DM7HUNW Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Testosterone. Low bone mass disorder [FB83] [22]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Thioguanine and Denosumab. Low bone mass disorder [FB83] [32]
Crizotinib DM4F29C Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Crizotinib. Lung cancer [2C25] [22]
Ceritinib DMB920Z Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Ceritinib. Lung cancer [2C25] [22]
Erlotinib DMCMBHA Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Erlotinib. Lung cancer [2C25] [22]
Lurbinectedin DMEFRTZ Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Lurbinectedin. Lung cancer [2C25] [22]
Alectinib DMP1I6Y Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Alectinib. Lung cancer [2C25] [22]
BIBW 2992 DMTKD7Q Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and BIBW 2992. Lung cancer [2C25] [22]
Pralsetinib DMWU0I2 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Pralsetinib. Lung cancer [2C25] [22]
Capmatinib DMYCXKL Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Capmatinib. Lung cancer [2C25] [22]
Selpercatinib DMZR15V Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Selpercatinib. Lung cancer [2C25] [22]
Sulphadoxine DMZI2UF Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Sulphadoxine. Malaria [1F40-1F45] [22]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [22]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [22]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Idelalisib. Mature B-cell leukaemia [2A82] [24]
IPI-145 DMWA24P Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and IPI-145. Mature B-cell leukaemia [2A82] [22]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Clofarabine. Mature B-cell lymphoma [2A85] [33]
Blinatumomab DMGECIJ Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Blinatumomab. Mature B-cell lymphoma [2A85] [22]
Vincristine DMINOX3 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Vincristine. Mature B-cell lymphoma [2A85] [22]
Mercaptopurine DMTM2IK Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Mercaptopurine. Mature B-cell lymphoma [2A85] [22]
Ponatinib DMYGJQO Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Ponatinib. Mature B-cell lymphoma [2A85] [22]
Cytarabine DMZD5QR Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Cytarabine. Mature B-cell lymphoma [2A85] [22]
Arry-162 DM1P6FR Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Arry-162. Melanoma [2C30] [22]
Vemurafenib DM62UG5 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Vemurafenib. Melanoma [2C30] [22]
Ipilimumab DMJTIYK Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Ipilimumab. Melanoma [2C30] [22]
Dacarbazine DMNPZL4 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Dacarbazine. Melanoma [2C30] [22]
Danazol DML8KTN Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Danazol. Menstrual cycle bleeding disorder [GA20] [22]
Exjade DMHPRWG Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Exjade. Mineral absorption/transport disorder [5C64] [22]
Riluzole DMECBWN Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Riluzole. Motor neuron disease [8B60] [22]
Carfilzomib DM48K0X Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Carfilzomib. Multiple myeloma [2A83] [22]
Panobinostat DM58WKG Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Panobinostat. Multiple myeloma [2A83] [22]
Lenalidomide DM6Q7U4 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Lenalidomide. Multiple myeloma [2A83] [22]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Thioguanine and Thalidomide. Multiple myeloma [2A83] [34]
Elotuzumab DMEYHG9 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Elotuzumab. Multiple myeloma [2A83] [22]
Tecfidera DM2OVDT Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Tecfidera. Multiple sclerosis [8A40] [22]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Thioguanine and Siponimod. Multiple sclerosis [8A40] [35]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Thioguanine and Fingolimod. Multiple sclerosis [8A40] [36]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Thioguanine and Ocrelizumab. Multiple sclerosis [8A40] [37]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Thioguanine and Ozanimod. Multiple sclerosis [8A40] [25]
Fedratinib DM4ZBK6 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Fedratinib. Myeloproliferative neoplasm [2A20] [22]
Nilotinib DM7HXWT Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Nilotinib. Myeloproliferative neoplasm [2A20] [22]
Imatinib DM7RJXL Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Imatinib. Myeloproliferative neoplasm [2A20] [22]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Thioguanine and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [38]
Bupropion DM5PCS7 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Bupropion. Nicotine use disorder [6C4A] [22]
Entrectinib DMMPTLH Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Entrectinib. Non-small cell lung cancer [2C25] [22]
Orlistat DMRJSP8 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Orlistat. Obesity [5B80-5B81] [22]
Rofecoxib DM3P5DA Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Rofecoxib. Osteoarthritis [FA00-FA05] [22]
Valdecoxib DMAY7H4 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Valdecoxib. Osteoarthritis [FA00-FA05] [22]
Diclofenac DMPIHLS Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Diclofenac. Osteoarthritis [FA00-FA05] [22]
Naproxen DMZ5RGV Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Naproxen. Osteoarthritis [FA00-FA05] [22]
Etodolac DM6WJO9 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Etodolac. Pain [MG30-MG3Z] [22]
Ibuprofen DM8VCBE Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Ibuprofen. Pain [MG30-MG3Z] [22]
Nabumetone DMAT2XH Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Nabumetone. Pain [MG30-MG3Z] [22]
Piroxicam DMTK234 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Piroxicam. Pain [MG30-MG3Z] [22]
Ketorolac DMI4EL5 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Ketorolac. Postoperative inflammation [1A00-CA43] [22]
Bromfenac DMKB79O Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Bromfenac. Postoperative inflammation [1A00-CA43] [22]
ABIRATERONE DM8V75C Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and ABIRATERONE. Prostate cancer [2C82] [22]
Nilutamide DMFN07X Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Nilutamide. Prostate cancer [2C82] [22]
Flutamide DMK0O7U Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Flutamide. Prostate cancer [2C82] [22]
Bicalutamide DMZMSPF Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Bicalutamide. Prostate cancer [2C82] [22]
Acitretin DM8BKU9 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Acitretin. Psoriasis [EA90] [22]
Ambrisentan DMD1QXW Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Ambrisentan. Pulmonary hypertension [BB01] [22]
Bosentan DMIOGBU Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Bosentan. Pulmonary hypertension [BB01] [22]
Axitinib DMGVH6N Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Axitinib. Renal cell carcinoma [2C90] [22]
Sorafenib DMS8IFC Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Sorafenib. Renal cell carcinoma [2C90] [22]
Gatifloxacin DMSL679 Minor Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [26]
Sulfadiazine DMTW3R8 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Sulfadiazine. Rheumatic fever [1B40] [22]
Meloxicam DM2AR7L Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Meloxicam. Rheumatoid arthritis [FA20] [22]
Sulindac DM2QHZU Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Sulindac. Rheumatoid arthritis [FA20] [22]
Celecoxib DM6LOQU Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Celecoxib. Rheumatoid arthritis [FA20] [22]
Tocilizumab DM7J6OR Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Tocilizumab. Rheumatoid arthritis [FA20] [22]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Thioguanine and Canakinumab. Rheumatoid arthritis [FA20] [39]
Oxaprozin DM9UB0P Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Oxaprozin. Rheumatoid arthritis [FA20] [22]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Thioguanine and Rilonacept. Rheumatoid arthritis [FA20] [39]
Flurbiprofen DMGN4BY Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Flurbiprofen. Rheumatoid arthritis [FA20] [22]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Thioguanine and Golimumab. Rheumatoid arthritis [FA20] [40]
Sulfasalazine DMICA9H Moderate Decreased metabolism of Thioguanine caused by Sulfasalazine mediated inhibition of non-CYP450 enzyme. Rheumatoid arthritis [FA20] [31]
Fenoprofen DML5VQ0 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Fenoprofen. Rheumatoid arthritis [FA20] [22]
Sarilumab DMOGNXY Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Sarilumab. Rheumatoid arthritis [FA20] [22]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Thioguanine and Leflunomide. Rheumatoid arthritis [FA20] [29]
Tolmetin DMWUIJE Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Tolmetin. Rheumatoid arthritis [FA20] [22]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Thioguanine when combined with Anthrax vaccine. Sepsis [1G40-1G41] [41]
Larotrectinib DM26CQR Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [22]
PDX-101 DM6OC53 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and PDX-101. Solid tumour/cancer [2A00-2F9Z] [22]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [25]
LEE011 DMMX75K Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and LEE011. Solid tumour/cancer [2A00-2F9Z] [22]
Gemcitabine DMSE3I7 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Gemcitabine. Solid tumour/cancer [2A00-2F9Z] [22]
Methyltestosterone DMWLFGO Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Methyltestosterone. Solid tumour/cancer [2A00-2F9Z] [22]
Disulfiram DMCL2OK Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Disulfiram. Substance abuse [6C40] [22]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Naltrexone. Substance abuse [6C40] [42]
Fostamatinib DM6AUHV Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Fostamatinib. Thrombocytopenia [3B64] [22]
Eltrombopag DMOGFIX Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Eltrombopag. Thrombocytopenia [3B64] [22]
Lenvatinib DMB1IU4 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Lenvatinib. Thyroid cancer [2D10] [22]
Methimazole DM25FL8 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Methimazole. Thyrotoxicosis [5A02] [22]
Propylthiouracil DM6D7N8 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Propylthiouracil. Thyrotoxicosis [5A02] [22]
Tizanidine DMR2IQ4 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Tizanidine. Tonus and reflex abnormality [MB47] [22]
Trimetrexate DMDEA85 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Trimetrexate. Toxoplasmosis [1F57] [22]
Azathioprine DMMZSXQ Moderate Additive immunosuppressive effects by the combination of Thioguanine and Azathioprine. Transplant rejection [NE84] [35]
Olsalazine DMZW9HA Moderate Decreased metabolism of Thioguanine caused by Olsalazine mediated inhibition of non-CYP450 enzyme. Ulcerative colitis [DD71] [31]
Cinoxacin DM4EWNS Minor Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Cinoxacin. Urinary tract infection [GC08] [26]
Nitrofurantoin DM7PQIK Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Nitrofurantoin. Urinary tract infection [GC08] [22]
Sulfamethizole DMGCHDS Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Sulfamethizole. Urinary tract infection [GC08] [22]
Nalidixic acid DMRM0JV Minor Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Nalidixic acid. Urinary tract infection [GC08] [26]
Enoxacin DMYTE6L Minor Decreased absorption of Thioguanine due to intestinal mucosa variation caused by Enoxacin. Urinary tract infection [GC08] [26]
Elagolix DMB2C0E Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Elagolix. Uterine fibroid [2E86] [22]
Amiodarone DMUTEX3 Moderate Increased risk of hepatotoxicity by the combination of Thioguanine and Amiodarone. Ventricular tachyarrhythmia [BC71] [22]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Thioguanine and Ganciclovir. Virus infection [1A24-1D9Z] [35]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Thioguanine and Valganciclovir. Virus infection [1A24-1D9Z] [35]
⏷ Show the Full List of 223 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Thioguanine 40 mg tablet 40 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Thioguanine FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6845).
4 Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res. 2015 Mar;115:9-16.
5 BDDCS applied to over 900 drugs
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8 Immune effector cells produce lethal DNA damage in cells treated with a thiopurine. Cancer Res. 2009 Mar 15;69(6):2393-9.
9 Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem Biophys Res Commun. 2006 Apr 28;343(1):208-15.
10 Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004 Feb;36(2):247-57.
11 ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012 Apr 15;83(8):1073-83.
12 Qualitative and quantitative difference in mutation induction between carbon- and neon-ion beams in normal human cells. Biol Sci Space. 2003 Dec;17(4):302-6.
13 Usefulness of thiopurine methyltransferase and thiopurine metabolite analysis in clinical practice in patients with inflammatory bowel diseases. Acta Gastroenterol Belg. 2010 Jul-Sep;73(3):331-5.
14 The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther. 2005 May;4(5):855-63.
15 Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 2000 May;6(5):1796-803.
16 Important role of caspase-8 for chemosensitivity of ALL cells. Clin Cancer Res. 2011 Dec 15;17(24):7605-13. doi: 10.1158/1078-0432.CCR-11-0513. Epub 2011 Oct 18.
17 The effect of Msh2 knockdown on methylating agent induced toxicity in DNA glycosylase deficient cells. Toxicology. 2010 Jan 31;268(1-2):111-7. doi: 10.1016/j.tox.2009.12.008. Epub 2009 Dec 16.
18 The effect of 6-thioguanine on alternative splicing and antisense-mediated exon skipping treatment for duchenne muscular dystrophy. PLoS Curr. 2012 Dec 12;4:ecurrents.md.597d700f92eaa70de261ea0d91821377. doi: 10.1371/currents.md.597d700f92eaa70de261ea0d91821377.
19 CRISPR/Cas9-mediated gene knockout screens and target identification via whole-genome sequencing uncover host genes required for picornavirus infection. J Biol Chem. 2017 Jun 23;292(25):10664-10671. doi: 10.1074/jbc.M117.782425. Epub 2017 Apr 26.
20 Petit E, Langouet S, Akhdar H, Nicolas-Nicolaz C, Guillouzo A, Morel F. Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. Toxicol In Vitro. 2008;22(3):632-642. [PMID: 18222062]
21 The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia. Clin Pharmacol Ther. 2006 Oct;80(4):375-83. doi: 10.1016/j.clpt.2006.07.002.
22 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
23 European Medicines Agency "Summary on compassionate use. Remdesivir Gilead.".
24 Product Information. Hivid (zalcitabine). Roche Laboratories, Nutley, NJ.
25 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
26 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
27 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
28 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
29 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
30 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
31 Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ "Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction [letter comment." Gastroenterology 116 (1999): 1505-6. [PMID: 10391741]
32 Product Information. Lonsurf (tipiracil-trifluridine). Taiho Oncology, Inc., Princeton, NJ.
33 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
34 Figg WD, Arlen P, Gulley J, et al. "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer." Semin Oncol 28(4 Suppl 15) (2001): 62-6. [PMID: 11685731]
35 Cerner Multum, Inc. "Australian Product Information.".
36 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
37 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
38 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
39 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
40 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
41 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
42 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.